1. Home
  2. CYTK vs CPT Comparison

CYTK vs CPT Comparison

Compare CYTK & CPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$80.44

Market Cap

10.7B

Sector

Health Care

ML Signal

HOLD

Logo Camden Property Trust

CPT

Camden Property Trust

HOLD

Current Price

$112.58

Market Cap

11.3B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
CPT
Founded
1997
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
10.7B
11.3B
IPO Year
2004
1995

Fundamental Metrics

Financial Performance
Metric
CYTK
CPT
Price
$80.44
$112.58
Analyst Decision
Strong Buy
Buy
Analyst Count
19
17
Target Price
$89.26
$115.28
AVG Volume (30 Days)
2.3M
928.4K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
4.03%
EPS Growth
N/A
136.00
EPS
N/A
0.40
Revenue
$13,368,000.00
$12,967,000.00
Revenue This Year
$7.37
N/A
Revenue Next Year
$310.19
$2.60
P/E Ratio
N/A
$286.80
Revenue Growth
N/A
81.69
52 Week Low
$32.89
$96.53
52 Week High
$88.31
$119.81

Technical Indicators

Market Signals
Indicator
CYTK
CPT
Relative Strength Index (RSI) 49.47 48.94
Support Level $59.07 $105.41
Resistance Level $88.31 $116.59
Average True Range (ATR) 2.98 2.12
MACD -0.86 -0.52
Stochastic Oscillator 21.81 12.35

Price Performance

Historical Comparison
CYTK
CPT

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About CPT Camden Property Trust

Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 175 multifamily properties comprised of nearly 59,921 apartment homes across the United States.

Share on Social Networks: